GlassScriptPhysician profile
Alfredo Antonetti
NPI 1043237761
$3,273.40
in general payments reported to CMS, 2019-2025
28 companies · $641 in 2025
The $641 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $96.99 · 2021: $339 · 2022: $661 · 2023: $1,114 · 2024: $296 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,978 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.37 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $774.09 | 2022-2024 | |
| Abbvie INC. | $463.74 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $439.66 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $273.45 | 2022-2025 | |
| Organon LLC | $255.27 | 2022-2025 | Nexplanon, Jada System |
| Motiva USA, LLC | $141.14 | 2025 | |
| Myovant Sciences INC. | $140.32 | 2021-2022 | |
| Aspira Women'S Health INC | $139.35 | 2019-2023 | Ova1 |
| Pfizer INC. | $89.45 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $64.98 | 2023 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $59.28 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $56.42 | 2021-2022 | |
| Allergan, INC. | $46.79 | 2019-2020 | |
| Exeltis, USA INC. | $46.64 | 2021-2024 | Slynd |
| Coopersurgical, INC. | $43.37 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $32.31 | 2023 | Balcoltra |
| Smith+Nephew, INC. | $27.88 | 2022 | |
| Shield Therapeutics INC | $21.90 | 2022 | |
| Vertical Pharmaceuticals, LLC | $19.64 | 2020 | |
| Mission Pharmacal Company | $18.10 | 2024 | Citranatal Medley |
| Evofem Biosciences, INC. | $17.05 | 2021 | |
| Therapeuticsmd, INC. | $16.56 | 2021 | |
| Roche Diagnostics Corporation | $16.25 | 2021 | |
| Millicent US INC | $15.60 | 2023 | Intrarosa |
| Pacira Pharmaceuticals Incorporated | $15.29 | 2025 | Exparel |
| Cumberland Pharmaceuticals, INC. | $14.90 | 2019 | |
| Meditrina | $12.27 | 2022 | |
| Merck Sharp & Dohme LLC | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Antonetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.